Skip to main content
Equibles
ABOS logo

ABOS · Acumen Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track ABOS — free

Use ABOS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ABOS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.09 +0.05 (+2.21%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Accordingly, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$159.46M
Shares
72.32M
Volume · Oct 5 464.89K Avg daily vol (3M) 420.36K

Acumen Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Acumen Pharmaceuticals, Inc. (ABOS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Capital Markets Day
Investor event
2026-09-16
Acumen Pharmaceuticals, Inc. (ABOS) September 2026 Capital Markets Day Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2026 Earnings Call Transcript
Confident tone Sobbernatug (SabernaTug) safety/tolerability differentiation Top-line ALTA-2/altitude readout expectations Mechanism and target (oligomers vs plaque)
Diluted EPS
$-0.45
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-12
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call Transcript
Positive tone EBD / blood-brain barrier program with JCR Altitude AD Phase II trial progress A-beta oligomer scientific thesis
Diluted EPS
$-0.33
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2025 Earnings Call Transcript
Confident tone EBD / next-generation program with JCR Altitude AD Phase II readout AD field sentiment and market opportunity
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2025 Earnings Call Transcript
Positive tone Sabirnetug Antibody Profile ACU234 Next-Generation Antibody ALTITUDE-AD Phase II Trial Progress
Diluted EPS
$-0.44
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2025 Earnings Call Transcript
Positive tone JCR Pharmaceuticals partnership (EBD program) ARIA safety profile Strategic portfolio expansion
Diluted EPS
$-0.68
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Confident tone Phase 2 ALTITUDE-AD enrollment completion and timeline Sabirnetug clinical profile and differentiation Biomarkers as treatment monitoring tools
Diluted EPS
$-0.48
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2024 Earnings Call Transcript
Confident tone Sabirnetug clinical development ARIA safety profile Enrollment progress and site activation
Diluted EPS
$-0.50
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2024 Earnings Call Transcript
Confident tone ALTITUDE-AD Phase 2 enrollment and execution Biomarker strategy (pTau217, synaptic markers) Competitive landscape and field validation
Diluted EPS
$-0.34
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-14
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript
Confident tone Subcutaneous Formulation Sabirnetug Clinical Profile and Differentiation ALTITUDE-AD Phase II Trial
Diluted EPS
$-0.25
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-26
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2023 Earnings Call Transcript
Confident tone Phase 1 INTERCEPT-AD results Sabirnetug (ACU193) drug profile Phase 2 ALTITUDE-AD study
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-13
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.24
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Acumen Pharmaceuticals, Inc. (ABOS) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.26
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-15
Acumen Pharmaceuticals, Inc. (ABOS) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.25
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-16
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2022 Earnings Call Transcript
Diluted EPS
$-0.23
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-28
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2021 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–21 of 21 webcasts
Key facts CIK 1576885 CUSIP 00509G209 13F (30d) 2 filings 2 filers Visit website Investor relations